Second malignant neoplasms in children treated for rhabdomyosarcoma

Ruth Heyn, Veronica Haeberlen, William A. Newton, Abdelsalam H. Ragab, R. Beverly Raney, Melvin Tefft, Moody Wharam, Lisa G. Ensign, Harold M. Maurer

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Purpose: This study was performed to determine the incidence and risk factors involved in the development of a second malignant neoplasm (SMN) after treatment of primary rhabdomyosarcoma (RMS) in patients enrolled onto Intergroup Rhabdomyosarcoma Studies I and II (IRS I and II). Patients and Methods: There were 1,770 patients with primary RMS entered onto IRS I and II between 1972 and 1984. They were treated with chemotherapy and, in most instances, radiotherapy according to randomized or assigned regimens based on clinical grouping. Median follow-up time for these patients was 8.4 years. Incidence density (ID) was calculated for each study and for treatment and age groups. The 10-year cumulative incidence was estimated for each study. Results: Twenty-two SMNs have been reported through 1991. The most common tumor type was a bone sarcoma followed by acute nonlymphoblastic leukemia (ANLL). The median time to the development of an SMN was 7 years (range, 1 11/12, to 15 9/13 years). The 10-year cumulative incidence rate was 1.7% for both studies. ID and cumulative incidence estimates were highest for patients who received both an alkylating agent and radiotherapy. The majority of patients for whom family histories were available had either neurofibromatosis themselves or a family history that suggested the Li-Fraumeni syndrome (LFS). Conclusion: The results of this study suggest that genetic abnormalities play a prominent role in the development of an SMN after therapy for a primary RMS. Chemotherapy with an alkylating agent and radiotherapy play significant roles in the development of an SMN compared with patients who received only one of these therapeutic modalities.

Original languageEnglish (US)
Pages (from-to)262-270
Number of pages9
JournalJournal of Clinical Oncology
Volume11
Issue number2
DOIs
StatePublished - Jan 1 1993

Fingerprint

Second Primary Neoplasms
Rhabdomyosarcoma
Incidence
Radiotherapy
Alkylating Agents
Li-Fraumeni Syndrome
Drug Therapy
Neurofibromatoses
Therapeutics
Acute Myeloid Leukemia
Sarcoma
Age Groups
Bone and Bones
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Heyn, R., Haeberlen, V., Newton, W. A., Ragab, A. H., Raney, R. B., Tefft, M., ... Maurer, H. M. (1993). Second malignant neoplasms in children treated for rhabdomyosarcoma. Journal of Clinical Oncology, 11(2), 262-270. https://doi.org/10.1200/JCO.1993.11.2.262

Second malignant neoplasms in children treated for rhabdomyosarcoma. / Heyn, Ruth; Haeberlen, Veronica; Newton, William A.; Ragab, Abdelsalam H.; Raney, R. Beverly; Tefft, Melvin; Wharam, Moody; Ensign, Lisa G.; Maurer, Harold M.

In: Journal of Clinical Oncology, Vol. 11, No. 2, 01.01.1993, p. 262-270.

Research output: Contribution to journalArticle

Heyn, R, Haeberlen, V, Newton, WA, Ragab, AH, Raney, RB, Tefft, M, Wharam, M, Ensign, LG & Maurer, HM 1993, 'Second malignant neoplasms in children treated for rhabdomyosarcoma', Journal of Clinical Oncology, vol. 11, no. 2, pp. 262-270. https://doi.org/10.1200/JCO.1993.11.2.262
Heyn R, Haeberlen V, Newton WA, Ragab AH, Raney RB, Tefft M et al. Second malignant neoplasms in children treated for rhabdomyosarcoma. Journal of Clinical Oncology. 1993 Jan 1;11(2):262-270. https://doi.org/10.1200/JCO.1993.11.2.262
Heyn, Ruth ; Haeberlen, Veronica ; Newton, William A. ; Ragab, Abdelsalam H. ; Raney, R. Beverly ; Tefft, Melvin ; Wharam, Moody ; Ensign, Lisa G. ; Maurer, Harold M. / Second malignant neoplasms in children treated for rhabdomyosarcoma. In: Journal of Clinical Oncology. 1993 ; Vol. 11, No. 2. pp. 262-270.
@article{d2b0a0e44c0d481cbc9fae20ca410242,
title = "Second malignant neoplasms in children treated for rhabdomyosarcoma",
abstract = "Purpose: This study was performed to determine the incidence and risk factors involved in the development of a second malignant neoplasm (SMN) after treatment of primary rhabdomyosarcoma (RMS) in patients enrolled onto Intergroup Rhabdomyosarcoma Studies I and II (IRS I and II). Patients and Methods: There were 1,770 patients with primary RMS entered onto IRS I and II between 1972 and 1984. They were treated with chemotherapy and, in most instances, radiotherapy according to randomized or assigned regimens based on clinical grouping. Median follow-up time for these patients was 8.4 years. Incidence density (ID) was calculated for each study and for treatment and age groups. The 10-year cumulative incidence was estimated for each study. Results: Twenty-two SMNs have been reported through 1991. The most common tumor type was a bone sarcoma followed by acute nonlymphoblastic leukemia (ANLL). The median time to the development of an SMN was 7 years (range, 1 11/12, to 15 9/13 years). The 10-year cumulative incidence rate was 1.7{\%} for both studies. ID and cumulative incidence estimates were highest for patients who received both an alkylating agent and radiotherapy. The majority of patients for whom family histories were available had either neurofibromatosis themselves or a family history that suggested the Li-Fraumeni syndrome (LFS). Conclusion: The results of this study suggest that genetic abnormalities play a prominent role in the development of an SMN after therapy for a primary RMS. Chemotherapy with an alkylating agent and radiotherapy play significant roles in the development of an SMN compared with patients who received only one of these therapeutic modalities.",
author = "Ruth Heyn and Veronica Haeberlen and Newton, {William A.} and Ragab, {Abdelsalam H.} and Raney, {R. Beverly} and Melvin Tefft and Moody Wharam and Ensign, {Lisa G.} and Maurer, {Harold M.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1200/JCO.1993.11.2.262",
language = "English (US)",
volume = "11",
pages = "262--270",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Second malignant neoplasms in children treated for rhabdomyosarcoma

AU - Heyn, Ruth

AU - Haeberlen, Veronica

AU - Newton, William A.

AU - Ragab, Abdelsalam H.

AU - Raney, R. Beverly

AU - Tefft, Melvin

AU - Wharam, Moody

AU - Ensign, Lisa G.

AU - Maurer, Harold M.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Purpose: This study was performed to determine the incidence and risk factors involved in the development of a second malignant neoplasm (SMN) after treatment of primary rhabdomyosarcoma (RMS) in patients enrolled onto Intergroup Rhabdomyosarcoma Studies I and II (IRS I and II). Patients and Methods: There were 1,770 patients with primary RMS entered onto IRS I and II between 1972 and 1984. They were treated with chemotherapy and, in most instances, radiotherapy according to randomized or assigned regimens based on clinical grouping. Median follow-up time for these patients was 8.4 years. Incidence density (ID) was calculated for each study and for treatment and age groups. The 10-year cumulative incidence was estimated for each study. Results: Twenty-two SMNs have been reported through 1991. The most common tumor type was a bone sarcoma followed by acute nonlymphoblastic leukemia (ANLL). The median time to the development of an SMN was 7 years (range, 1 11/12, to 15 9/13 years). The 10-year cumulative incidence rate was 1.7% for both studies. ID and cumulative incidence estimates were highest for patients who received both an alkylating agent and radiotherapy. The majority of patients for whom family histories were available had either neurofibromatosis themselves or a family history that suggested the Li-Fraumeni syndrome (LFS). Conclusion: The results of this study suggest that genetic abnormalities play a prominent role in the development of an SMN after therapy for a primary RMS. Chemotherapy with an alkylating agent and radiotherapy play significant roles in the development of an SMN compared with patients who received only one of these therapeutic modalities.

AB - Purpose: This study was performed to determine the incidence and risk factors involved in the development of a second malignant neoplasm (SMN) after treatment of primary rhabdomyosarcoma (RMS) in patients enrolled onto Intergroup Rhabdomyosarcoma Studies I and II (IRS I and II). Patients and Methods: There were 1,770 patients with primary RMS entered onto IRS I and II between 1972 and 1984. They were treated with chemotherapy and, in most instances, radiotherapy according to randomized or assigned regimens based on clinical grouping. Median follow-up time for these patients was 8.4 years. Incidence density (ID) was calculated for each study and for treatment and age groups. The 10-year cumulative incidence was estimated for each study. Results: Twenty-two SMNs have been reported through 1991. The most common tumor type was a bone sarcoma followed by acute nonlymphoblastic leukemia (ANLL). The median time to the development of an SMN was 7 years (range, 1 11/12, to 15 9/13 years). The 10-year cumulative incidence rate was 1.7% for both studies. ID and cumulative incidence estimates were highest for patients who received both an alkylating agent and radiotherapy. The majority of patients for whom family histories were available had either neurofibromatosis themselves or a family history that suggested the Li-Fraumeni syndrome (LFS). Conclusion: The results of this study suggest that genetic abnormalities play a prominent role in the development of an SMN after therapy for a primary RMS. Chemotherapy with an alkylating agent and radiotherapy play significant roles in the development of an SMN compared with patients who received only one of these therapeutic modalities.

UR - http://www.scopus.com/inward/record.url?scp=0027447448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027447448&partnerID=8YFLogxK

U2 - 10.1200/JCO.1993.11.2.262

DO - 10.1200/JCO.1993.11.2.262

M3 - Article

C2 - 8426203

AN - SCOPUS:0027447448

VL - 11

SP - 262

EP - 270

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -